ㅁ Add-on 가능: 고객의 요청에 따라 일정한 범위 내에서 Customization이 가능합니다. 자세한 사항은 문의해 주시기 바랍니다.
ㅁ 보고서에 따라 최신 정보로 업데이트하여 보내드립니다. 배송기일은 문의해 주시기 바랍니다.
한글목차
테넥테플라제(TNKase) 시장 규모는 향후 몇 년간 강한 성장을 기록할 것으로 예상됩니다. 예측 기간 동안의 성장은 고령화 인구, 심혈관 질환의 증가, 의료 접근성 확대, 혈전 용해 치료법의 발전, 의료 지출 증가 등에 기인할 것으로 분석됩니다. 예측 기간 동안 주요 트렌드에는 맞춤형 의료, AI 기반 진단, 현장 진단 검사, 외래 진료로의 전환, 디지털 헬스케어 통합 등이 포함됩니다.
뇌졸중 환자의 증가가 향후 몇 년간 테넥테플라제(TNKase) 시장 성장을 촉진할 것으로 예상됩니다. 뇌졸중은 뇌 혈관의 막힘이나 파열로 인해 뇌 기능이 갑자기 손실되는 질환입니다. 뇌졸중 발생률의 증가는 고령화 인구, 불건강한 생활 방식, 기저 질환 등 다양한 요인에 기인합니다. 테넥테플라제(TNKase)는 조직 플라스미노겐 활성화제(tPA)로, 뇌로 혈류를 차단하는 혈전을 신속히 분해하여 혈류를 회복시키고 뇌 손상을 최소화합니다. 이는 증상 발현 후 중요한 시간 창 내에 투여될 경우 환자 예후 개선에 필수적입니다. 예를 들어, 2024년 9월 미국 미네소타주 보건부(Minnesota Department of Health)는 2023년 미네소타주 성인 중 약 3.1%인 약 14만 명이 뇌졸중을 경험했다고 보고했습니다. 또한 2022년에는 급성 뇌졸중으로 인해 해당 주에서 약 1만 3,000건의 입원 사례가 발생했습니다. 따라서 뇌졸중 사례의 증가가 테넥테플라제(TNKase) 시장 성장에 기여하고 있습니다.
심혈관 질환의 유병률 증가가 테넥테플라제(TNKase) 시장 성장을 더욱 촉진할 것으로 예상됩니다. 심혈관 질환은 심장 질환과 고혈압 등 심장과 혈관 장애를 포함합니다. 이러한 질환의 유병률 증가의 주요 원인은 불균형한 식습관, 신체 활동 부족, 흡연, 비만 및 당뇨병의 증가 등 생활 방식 요인입니다. 테넥테플라제(TNKase)는 심혈관 질환 환자에게 치료 창구 내 투여 시 관상동맥을 막는 혈전을 신속히 용해시켜 혈류 회복, 심근 손상 감소, 급성 심근경색 등 질환에서의 생존율을 개선합니다. 예를 들어, 2024년 9월 영국 기반 심혈관 연구 자선 단체인 영국 심장 재단(British Heart Foundation)은 영국에서 약 760만 명이 심장 및 순환기 질환으로 고통받고 있으며, 이 중 약 400만 명은 남성, 360만 명은 여성이라고 보고했습니다. 이러한 질환은 영국 전체 사망의 약 27%를 차지하며, 연간 17만 명 이상의 사망을 초래합니다. 따라서 심혈관 질환의 발생률 증가가 테넥테플라제(TNKase) 시장 성장을 촉진하고 있습니다.
목차
제1장 주요 요약
제2장 시장 특징
제3장 바이오의약품 시장에서의 제품 특성
분자 유형
투여경로(ROA)
작용기전(MOA)
안전성과 유효성
제4장 시장 동향과 전략
제5장 시장 - 거시경제 시나리오 금리, 인플레이션, 지정학, 신형 코로나 바이러스 감염, 경기 회복이 시장에 미치는 영향을 포함한 거시경제 시나리오
제6장 세계의 성장 분석과 전략 분석 프레임워크
세계의 테넥테플라제(TNKase) : PESTEL 분석(정치, 사회, 기술, 환경, 법적 요인, 촉진요인과 억제요인)
최종 이용 산업의 분석
세계의 테넥테플라제(TNKase) 시장 : 성장률 분석
세계의 테넥테플라제(TNKase) 시장 실적 : 규모와 성장(2019-2024년)
세계의 테넥테플라제(TNKase) 시장 예측 : 규모와 성장(2024-2029년, 2034년)
세계의 테넥테플라제(TNKase) : 전체 시장 규모(TAM)
제7장 세계 시장의 가격 분석과 예측
제8장 시장 세분화
세계의 테넥테플라제(TNKase) 시장 : 투여별, 분석과 예측(2019-2024년, 2024-2029년, 2043년)
정맥내
카테터내
세계의 테넥테플라제(TNKase) 시장 : 용도별, 분석과 예측(2019-2024년, 2024-2029년, 2043년)
심근경색
뇌졸중
심부정맥혈전증
세계의 테넥테플라제(TNKase) 시장 : 최종 사용자별, 분석과 예측(2019-2024년, 2024-2029년, 2043년)
병원 및 클리닉
수술센터
연구센터
기타
제9장 임상적응증 세계 시장 역학
약제의 부작용
임상적응증의 발병률과 유병률
제10장 지역별, 국가별 분석
세계의 테넥테플라제(TNKase) 시장 : 지역별, 분석과 예측(2019-2024년, 2024-2029년, 2043년)
세계의 테넥테플라제(TNKase) 시장 : 국가별, 분석과 예측(2019-2024년, 2024-2029년, 2043년)
제11장 아시아태평양 시장
제12장 중국 시장
제13장 인도 시장
제14장 일본 시장
제15장 호주 시장
제16장 한국 시장
제17장 서유럽 시장
제18장 영국 시장
제19장 독일 시장
제20장 프랑스 시장
제21장 동유럽 시장
제22장 북미 시장
제23장 미국 시장
제24장 캐나다 시장
제25장 남미 시장
제26장 중동 시장
제27장 아프리카 시장
제28장 경쟁 구도와 기업 프로파일
테넥테플라제(TNKase) 시장 : 경쟁 구도
테넥테플라제(TNKase) 시장 : 기업 프로파일
Roche Holdings Inc.
제29장 세계 시장 : 파이프라인 분석
제30장 세계 시장 경쟁 벤치마킹과 대시보드
제31장 주요 인수합병(M&A)
제32장 최근 시장 동향
제33장 시장의 잠재력이 높은 국가, 전략
테넥테플라제(TNKase) 시장(2029년) : 새로운 기회를 제공하는 국가
테넥테플라제(TNKase) 시장(2029년) : 새로운 기회를 제공하는 부문
테넥테플라제(TNKase) 시장(2029년) : 성장 전략
시장 동향에 의한 전략
경쟁 전략
제34장 부록
HBR
영문 목차
영문목차
Tenecteplase (TNKase) is a recombinant tissue plasminogen activator (rtPA) used to treat acute ischemic stroke and specific types of heart attacks, such as STEMI. It works by breaking down blood clots to restore blood flow. Tenecteplase is known for its quicker administration and longer half-life compared to other rtPAs like alteplase.
Note that the outlook for this market is being affected by rapid changes in trade relations and tariffs globally. The report will be updated prior to delivery to reflect the latest status, including revised forecasts and quantified impact analysis. The report's Recommendations and Conclusions sections will be updated to give strategies for entities dealing with the fast-moving international environment.
The primary dosages of tenecteplase (TNKase) include intravenous dosage and intracatheter instillation. Intravenous administration involves injecting the medication directly into a patient's vein through a needle or catheter, allowing it to be quickly absorbed into the bloodstream for fast and effective delivery. This method is commonly used in thrombolytic therapies like Tenecteplase for conditions such as stroke, where rapid clot dissolution is essential for restoring brain blood flow. Tenecteplase has various applications in treating myocardial infarction, stroke, and deep vein thrombosis, and it is used by end-users such as hospitals, clinics, surgical centers, research centers, and others.
The tenecteplase (TNKase) market research report is one of a series of new reports from The Business Research Company that provides tenecteplase (TNKase) market statistics, including the tenecteplase (TNKase) industry's global market size, regional shares, competitors with a tenecteplase (TNKase) market share, detailed tenecteplase (TNKase) market segments, market trends and opportunities, and any further data you may need to thrive in the tenecteplase (TNKase) industry. This tenecteplase (TNKase) market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenarios of the industry.
The tenecteplase (TNKase) market size is expected to see strong growth in the next few years. It will grow to $2,253.7 million in 2029 at a compound annual growth rate (CAGR) of 6%. The growth in the forecast period can be attributed to an aging population, rising cardiovascular disease, expanding healthcare access, advancements in thrombolytic therapies, and growing healthcare expenditure. Major trends in the forecast period include personalized medicine, AI-driven diagnostics, point-of-care testing, shift toward outpatient care, and digital health integration.
The increasing number of stroke cases is expected to drive the growth of the tenecteplase (TNKase) market in the coming years. Stroke occurs when there is a sudden loss of brain function due to the blockage or rupture of blood vessels in the brain. The rising incidence of strokes can be attributed to factors such as aging populations, unhealthy lifestyles, and underlying health conditions. Tenecteplase (TNKase), a tissue plasminogen activator (tPA), helps stroke patients by rapidly breaking down blood clots that obstruct blood flow to the brain, restoring circulation, and minimizing brain damage. This is essential for improving patient outcomes when administered within the critical window following symptom onset. For example, in September 2024, the Minnesota Department of Health, a U.S.-based health agency, reported that around 3.1% of adults in Minnesota, or nearly 140,000 individuals, had experienced a stroke in 2023. Additionally, in 2022, there were about 13,000 hospitalizations in the state due to acute stroke events. Hence, the rising number of stroke cases is contributing to the growth of the tenecteplase (TNKase) market.
The rising prevalence of cardiovascular diseases is expected to further drive the growth of the tenecteplase (TNKase) market. Cardiovascular diseases include a variety of heart and blood vessel disorders, such as heart disease and hypertension. The increasing prevalence of these diseases is largely due to lifestyle factors such as poor diet, lack of physical activity, smoking, and rising obesity and diabetes rates. Tenecteplase (TNKase) aids patients with cardiovascular diseases by quickly dissolving blood clots that block coronary arteries, restoring blood flow, reducing heart muscle damage, and improving survival rates in conditions like acute myocardial infarction when administered within the therapeutic window. For instance, in September 2024, the British Heart Foundation, a UK-based cardiovascular research charity, reported that approximately 7.6 million people in the UK are affected by heart and circulatory diseases, with about 4 million males and 3.6 million females living with these conditions. These diseases account for approximately 27% of all deaths in the UK, leading to over 170,000 deaths annually. Therefore, the rising prevalence of cardiovascular diseases is driving the growth of the tenecteplase (TNKase) market.
The increasing aging population is expected to drive the growth of the tenecteplase (TNKase) market. An aging population refers to the demographic shift where the number of individuals aged 65 and above increases, typically due to longer life expectancies and lower birth rates. This trend is driven by advancements in healthcare and longer lifespans, leading to a higher prevalence of age-related diseases. Older adults often require treatments like tenecteplase (TNKase) for conditions such as myocardial infarction, which are more common in this age group. For example, in July 2024, the Office of National Statistics, a UK-based organization that produces official statistics, reported that in 2022, the UK had approximately 12.7 million people aged 65 and over, making up 19% of the total population. Projections indicate that by 2072, this number could rise to 22.1 million, accounting for 27% of the population. Therefore, the growing aging population is contributing to the growth of the tenecteplase (TNKase) market.
Key player operating in the tenecteplase (tnkase) market is Roche Holdings Inc.
North America was the largest region in the Tenecteplase (TNKase) market in 2024. The regions covered in tenecteplase (TNKase) report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa.
The countries covered in the tenecteplase (TNKase) market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.
The tenecteplase (TNKase) market consists of sales of TNKase (Tenecteplase) injection and powder. Values in this market are 'factory gate' values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.
The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).
The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.
Tenecteplase (TNKase) Global Market Report 2025 from The Business Research Company provides strategists, marketers and senior management with the critical information they need to assess the market.
This report focuses on tenecteplase (tnkase) market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.
Reasons to Purchase
Gain a truly global perspective with the most comprehensive report available on this market covering 10 geographies.
Assess the impact of key macro factors such as conflict, pandemic and recovery, inflation and interest rate environment and the 2nd Trump presidency.
Create regional and country strategies on the basis of local data and analysis.
Identify growth segments for investment.
Outperform competitors using forecast data and the drivers and trends shaping the market.
Understand customers based on the latest market shares.
Benchmark performance against key competitors.
Suitable for supporting your internal and external presentations with reliable high quality data and analysis
Report will be updated with the latest data and delivered to you within 3-4 working days of order along with an Excel data sheet for easy data extraction and analysis.
All data from the report will also be delivered in an excel dashboard format.
Where is the largest and fastest growing market for tenecteplase (tnkase) ? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward? The tenecteplase (tnkase) market global report from the Business Research Company answers all these questions and many more.
The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, competitive landscape, market shares, trends and strategies for this market. It traces the market's historic and forecast market growth by geography.
The market characteristics section of the report defines and explains the market.
The market size section gives the market size ($b) covering both the historic growth of the market, and forecasting its development.
The forecasts are made after considering the major factors currently impacting the market. These include:
The forecasts are made after considering the major factors currently impacting the market. These include the Russia-Ukraine war, rising inflation, higher interest rates, and the legacy of the COVID-19 pandemic.
Market segmentations break down the market into sub markets.
The regional and country breakdowns section gives an analysis of the market in each geography and the size of the market by geography and compares their historic and forecast growth. It covers the growth trajectory of COVID-19 for all regions, key developed countries and major emerging markets.
The competitive landscape chapter gives a description of the competitive nature of the market, market shares, and a description of the leading companies. Key financial deals which have shaped the market in recent years are identified.
The trends and strategies section analyses the shape of the market as it emerges from the crisis and suggests how companies can grow as the market recovers.
Scope
Markets Covered:1) By Dosage: Intravenous Dosage; Intracatheter Instillation
2) By Application: Myocardial Infarction; Stroke; Deep Vein Thrombosis
3) By End-user: Hospitals And Clinics; Surgical Centers; Research Centers; Others End-User
Regions: Asia-Pacific; Western Europe; Eastern Europe; North America; South America; Middle East; Africa
Time series: Five years historic and ten years forecast.
Data: Ratios of market size and growth to related markets, GDP proportions, expenditure per capita,
Data segmentations: country and regional historic and forecast data, market share of competitors, market segments.
Sourcing and Referencing: Data and analysis throughout the report is sourced using end notes.
Delivery format: PDF, Word and Excel Data Dashboard.
Table of Contents
1. Executive Summary
2. Tenecteplase (TNKase) Market Characteristics
3. Tenecteplase (TNKase) Market Biologic Drug Characteristics
3.1. Molecule Type
3.2. Route Of Administration (ROA)
3.3. Mechanism Of Action (MOA)
3.4. Safety And Efficacy
4. Tenecteplase (TNKase) Market Trends And Strategies
5. Tenecteplase (TNKase) Market - Macro Economic Scenario Macro Economic Scenario Including The Impact Of Interest Rates, Inflation, Geopolitics, Covid And Recovery On The Market
6. Global Tenecteplase (TNKase) Growth Analysis And Strategic Analysis Framework
6.1. Global Tenecteplase (TNKase) PESTEL Analysis (Political, Social, Technological, Environmental and Legal Factors, Drivers and Restraints)
6.2. Analysis Of End Use Industries
6.3. Global Tenecteplase (TNKase) Market Growth Rate Analysis
6.4. Global Tenecteplase (TNKase) Historic Market Size and Growth, 2019 - 2024, Value ($ Billion)
6.5. Global Tenecteplase (TNKase) Forecast Market Size and Growth, 2024 - 2029, 2034F, Value ($ Billion)
6.6. Global Tenecteplase (TNKase) Total Addressable Market (TAM)
7. Global Tenecteplase (TNKase) Market Pricing Analysis & Forecasts
8. Tenecteplase (TNKase) Market Segmentation
8.1. Global Tenecteplase (TNKase) Market, Segmentation By Dosage, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
Intravenous Dosage
Intracatheter Instillation
8.2. Global Tenecteplase (TNKase) Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
Myocardial Infarction
Stroke
Deep Vein Thrombosis
8.3. Global Tenecteplase (TNKase) Market, Segmentation By End-user, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
Hospitals And Clinics
Surgical Centers
Research Centers
Others End-User
9. Global Tenecteplase (TNKase) Market Epidemiology Of Clinical Indications
9.1. Drug Side Effects
9.2. Incidence And Prevalence of Clinical Indications
10. Tenecteplase (TNKase) Market Regional And Country Analysis
10.1. Global Tenecteplase (TNKase) Market, Split By Region, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
10.2. Global Tenecteplase (TNKase) Market, Split By Country, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
